SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanofi India informs about change in management

17 Oct 2023 Evaluate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (‘Listing Regulations’), Sanofi India has informed that with effect from 16th October 2023, Surabhi Kaul is appointed as India People Director and will be part of the Senior Management Personnel of the Company. Further, the information required in terms of Regulation 30 read with Schedule Ill - Para A (7) of Part A of the SEBI Listing Regulations and SEBI Circular bearing Ref. No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023 is enclosed as ‘Annexure-I’ to this letter.

The above information is a part of company’s filings submitted to BSE.

Sanofi India Share Price

3530.95 -56.25 (-1.57%)
22-Apr-2026 10:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1657.80
Dr. Reddys Lab 1213.85
Cipla 1227.60
Zydus Lifesciences 926.65
Lupin 2297.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×